Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis
American Journal of Hematology · 2026-07 · 101 (7) · 1729-1736
DOI: 10.1002/ajh.70327 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 25.04.2026. Verfasst von Elias Jabbour und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit nennt 14 Literaturangaben. Gefördert von: NIH/NCI.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Hannah Goulart, Koji Sasaki, Caitlin R Rausch, Tapan M Kadia, Farhad Ravandi, Danielle Hammond, Mahesh Swaminathan
Förderung
- NIH/NCI
Zitieren
APA
Jabbour, E., Goulart, H., Sasaki, K., Rausch, C. R., Jain, N., Kadia, T. M., DiNardo, C., Daver, N., Pemmaraju, N., Ravandi, F., Montalban-Bravo, G., Garcia-Manero, G., Hammond, D., Swaminathan, M., Hachem, M., Khouri, R., Ohanian, M., Garris, R., Short, N. J., & Kantarjian, H. M. (2026). Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis. American Journal of Hematology, 101(7), 1729-1736. https://doi.org/10.1002/ajh.70327
Vancouver
Jabbour E, Goulart H, Sasaki K, Rausch CR, Jain N, Kadia TM, et al. Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis. American Journal of Hematology. 2026;101(7):1729-1736. doi:10.1002/ajh.70327
BibTeX
@article{Jabbour2026,
author = {Jabbour, Elias and Goulart, Hannah and Sasaki, Koji and Rausch, Caitlin R and Jain, Nitin and Kadia, Tapan M and DiNardo, Courtney and Daver, Naval and Pemmaraju, Naveen and Ravandi, Farhad and Montalban-Bravo, Guillermo and Garcia-Manero, Guillermo and Hammond, Danielle and Swaminathan, Mahesh and Hachem, Maria and Khouri, Rita and Ohanian, Maro and Garris, Rebecca and Short, Nicholas J and Kantarjian, Hagop M},
title = {Hyper‐ CVAD Versus Hyper‐ CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {7},
pages = {1729--1736},
doi = {10.1002/ajh.70327}
}
EUVIMED